ARTAX BIOPHARMA

Artax Biopharma is a Phase 2 clinical-stage biotechnology company dedicated to the development of safe and effective treatments for autoimmune diseases. Rather than suppressing or blocking the immune response, our approach focuses on modulating activation at the T cell receptor. This prevents self-activation without causing immune suppression. We have a pipeline of first-in-class, fully proprietary Nck modulator candidates. Our lead program AX-158 showed compelling biomarker and clinical data in psoriasis patients in Phase 2a, in addition to convincing preclinical and Phase 1 data packages. We anticipate initiation of Phase 2 clinical trials with AX-158 in atopic dermatitis and at least one additional autoimmune indication in 2025, as we accelerate efforts to deliver Nck modulators to patients... A healthy immune system eliminates harmful foreign pathogens, while being tolerant of self-tissues and organs. When the immune system malfunctions and the T cell receptor (TCR) and..

Also known as: Artax Biopharma, Inc.

Primary location: Cambridge United States